Abstract
Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL)
Journal of clinical oncology, Vol.39(15_suppl), pp.e13569-e13569
05/20/2021
DOI: 10.1200/JCO.2021.39.15_suppl.e13569
Abstract
e13569
Background: Progress in understanding the molecular biology of DLBCL has led to development of complex molecular classifications that rely on sequencing methods. These molecular clusters are defined by activation of distinct pathways and may aid in selecting targeted therapy. In the molecular era, tissue requirements in clinical trials have increased to ensure sufficient tissue for molecular testing, potentially resulting in bias for enrollment of patients with larger excisional biopsies (EB). We examined the impact of tissue biopsy method on outcomes of DLBCL in a prospective observational study. Methods: Consecutive adult patients with DLBCL within 9 months from their initial diagnosis were enrolled into the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence (SPORE). Demographics, clinical variables, type of tissue biopsy (EB vs. core needle biopsy (CNB)) for initial diagnosis and initial treatment were recorded at baseline. Pts were contacted every 6 months from the date of diagnosis for first 3 years and then annually thereafter. Study objectives were event free survival (EFS) and overall survival (OS) by tissue biopsy method. Results: A total of 1061 patients with newly diagnosed DLBCL, from 2002 to 2015, were included. The table lists baseline characteristics of the cohort. 593 (56%) pts underwent EB and 468 (44%) underwent CNB for initial diagnosis. A significantly higher proportion of patients receiving CNB had performance status >=2, advanced stage, high risk disease by international prognostic index (IPI), abnormal lactate dehydrogenase. Median time from diagnosis to treatment initiation (DTI) was significantly shorter in the CNB group (13 days) than EB group (19 days). 2-year EFS (60% vs 75%, HR 0.75 (0.6-0.9), p <0.01) was significantly lower in CNB than EB group. There was a trend towards lower OS (75% vs 80%, HR: 0.8 (0.6-0.95), p =0.049) in CNB than EB group. Conclusions: Patients undergoing CNB are more likely to have higher risk disease, shorter DTI and survival compared to those undergoing EB. A need for large amount of diagnostic tissue in biomarker driven clinical trials may result in disproportional exclusion of high risk DLBCL pts who have inferior outcomes after standard treatment and could potentially benefit from novel agents, resulting in overperformance of the control arm. The need for tissue must be carefully balanced against resulting selection bias.[Table: see text]
Details
- Title: Subtitle
- Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL)
- Creators
- Sanjal Desai - Mayo ClinicRaphael Mwangi - Mayo ClinicRebecca L. King - Mayo ClinicMatthew J. Maurer - Mayo ClinicJames Robert Cerhan - Mayo ClinicAndew L. Feldman - Mayo Clinic Rochester, MNThomas Matthew Habermann - Mayo ClinicEric Mou - Stanford Health CareUmar Farooq - University of IowaCarrie A. Thompson - Mayo ClinicYucai Wang - Mayo ClinicThomas E. Witzig - Mayo ClinicGrzegorz S. Nowakowski - Mayo Clinic
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.39(15_suppl), pp.e13569-e13569
- DOI
- 10.1200/JCO.2021.39.15_suppl.e13569
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: None
- Language
- English
- Date published
- 05/20/2021
- Academic Unit
- Epidemiology; Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362343202771
Metrics
13 Record Views